Hip Pelvis.  2015 Mar;27(1):9-16. 10.5371/hp.2015.27.1.9.

Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures

Affiliations
  • 1Department of Orthopaedic Surgery, Keimyung University Dongsan Medical Center, Daegu, Korea. min@dsmc.or.kr

Abstract

Osteoporosis is a metabolic disease that is increasing in prevalence as people live longer. Because the orthopedic surgeon is frequently the first and often the only physician to manage patients with osteoporotic hip fractures, every effort should be made to prevent future fractures. A multidisciplinary approach is essential in treatment of osteoporotic fractures. Basic treatment includes calcium and vitamin D supplementation, fall prevention, hip protection, and balance and exercise programs. Currently available pharmacologic agents are divided into antiresorptive and anabolic groups. Antiresorptive agents such as bisphosphonates limit bone resorption through inhibition of osteoclastic activity. Anabolic agents such as parathyroid hormone promote bone formation.

Keyword

Osteoporosis; Medication; Hip fractures

MeSH Terms

Anabolic Agents
Bone Density Conservation Agents
Bone Resorption
Calcium
Diphosphonates
Hip
Hip Fractures*
Humans
Metabolic Diseases
Orthopedics
Osteoclasts
Osteogenesis
Osteoporosis
Osteoporotic Fractures
Parathyroid Hormone
Prevalence
Vitamin D
Anabolic Agents
Bone Density Conservation Agents
Calcium
Diphosphonates
Parathyroid Hormone
Vitamin D

Figure

  • Fig. 1 A 77-year-old wonam who underwent teeth extraction followed-by osteonecrosis of mandible.

  • Fig. 2 Radiological characteristics of atypical femoral fractures. 1: localized endosteal thickening, 2: transverse fracture pattern, 3: medial spike, 4: localized periosteal thickening at fracture site.

  • Fig. 3 Contralateral incomplete atypical subtrochanteric fracture. Arrow: localized periosteal thickening (beaking or flaring).

  • Fig. 4 Elliptical lateral cortical buckling. Arrow: localized periosteal thickening (beaking or flaring).


Cited by  1 articles

Clinical Results of Complex Subtrochanteric Femoral Fractures with Long Cephalomedullary Hip Nail
Kwang-kyoun Kim, Yougun Won, Danica H. Smith, Gi-Soo Lee, Hee Young Lee
Hip Pelvis. 2017;29(2):113-119.    doi: 10.5371/hp.2017.29.2.113.


Reference

1. Shea B, Wells G, Cranney A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis VII Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002; 23:552–559.
Article
2. Warensjö E, Byberg L, Melhus H, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ. 2011; 342:d1473.
Article
3. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341:c3691.
Article
4. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008; 336:262–266.
Article
5. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011; 342:d2040.
Article
6. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res. 2011; 26:35–41.
Article
7. Paik JM, Curhan GC, Sun Q, et al. Calcium supplement intake and risk of cardiovascular disease in women. Osteoporos Int. 2014; 25:2047–2056.
Article
8. Papaioannou A, Morin S, Cheung AM, et al. Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182:1864–1873.
Article
9. Karlsson MK, Gerdhem P, Ahlborg HG. The prevention of osteoporotic fractures. J Bone Joint Surg Br. 2005; 87:1320–1327.
Article
10. Black DM, Cummings SR, Karpf DB, et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:1535–1541.
Article
11. Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE. DXA-based hip structural analysis of onceweekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int. 2009; 20:911–921.
Article
12. Lee YK, Nho JH, Ha YC, Koo KH. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012; 23:2329–2333.
Article
13. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011; 96:2675–2680.
Article
14. Chang JI, Hazboun RC, Chang TI. Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72:2381.
Article
15. Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res. 2001; 16:437–440.
Article
16. Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br. 2012; 94:956–960.
Article
17. Li YT, Cai HF, Zhang ZL. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2015; 26:431–441.
Article
18. Komatsubara S, Mori S, Mashiba T, et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res. 2003; 18:512–520.
Article
19. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res. 2004; 19:999–1005.
Article
20. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294–1301.
Article
21. Lenart BA, Neviaser AS, Lyman S, et al. Association of lowenergy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009; 20:1353–1362.
Article
22. Shane E, Burr D, Ebeling PR, et al. American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25:2267–2294.
Article
23. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29:1–23.
Article
24. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010; 92:679–686.
Article
25. Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after longterm bisphosphonate therapy? Clin Orthop Relat Res. 2010; 468:3393–3398.
Article
26. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349:523–534.
Article
27. Ettinger B, Black DM, Mitlak BH, et al. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282:637–645.
Article
28. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001; 65:125–134.
Article
29. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008; 23:525–535.
Article
30. Black DM, Greenspan SL, Ensrud KE, et al. PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349:1207–1215.
Article
31. Ito M, Oishi R, Fukunaga M, et al. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporos Int. 2014; 25:1163–1172.
Article
32. Kawada T. Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int. 2014; 25:2321.
Article
33. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab. 2002; 87:2060–2066.
Article
34. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350:459–468.
Article
35. Bolland MJ, Grey A. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open. 2014; 4:e005787.
Article
36. Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361:756–765.
Article
37. Miller PD, Bolognese MA, Lewiecki EM, et al. Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43:222–229.
Article
38. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005; 57:973–993.
Article
Full Text Links
  • HP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr